Imaging in its Heyday: Clinical Applications (Part II)

As scientific innovation in molecular imaging explodes, experts believe the big payoff will be in clinical, rather than research, applications. But absent validating clinical data, businesses remain hesitant to jump into the field.

By Wendy Diller

In February of this year, the FDA approved the first radioimmunotherapy in the US, Idec Pharmaceuticals Corp. 's ibritumomab tiuxetan (Zevalin), a monoclonal antibody attached to a radioisotope indicated for treatment of certain kinds of B-cell non-Hodgkin's lymphoma. Zevalin is exciting not only because it is an effective therapy in refractory patients, but because it also demonstrates a concept that is of growing interest to diagnostic imaging experts, the ability to link a diagnostic imaging agent to a therapeutic

More from Strategy

More from Business